Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q5VWK5

UPID:
IL23R_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q5VWK5; C9JGX4; Q4VGP1; Q4VGP2; Q4VGP3; Q4VGP4; Q4VGP5; Q4VGP6; Q5VWK7; Q8IW84; Q8NFQ9; Q96AS1

BACKGROUND:
The Interleukin-23 receptor, integral to immune system functionality, associates with IL12RB1 to mediate critical cellular responses. By binding IL23, it activates the Jak-Stat pathway, essential for T-cell, NK cell, and macrophage/myeloid cell activation. This receptor's role extends to both the innate and adaptive immune systems, highlighting its importance in defending against infections and in the body's overall immune regulation.

THERAPEUTIC SIGNIFICANCE:
The receptor's involvement in Inflammatory bowel disease 17, which includes Crohn's disease and ulcerative colitis, underscores its therapeutic potential. These diseases, marked by gastrointestinal inflammation, could benefit from targeted therapies aimed at the Interleukin-23 receptor. Exploring this receptor's mechanisms offers promising avenues for developing treatments that could alleviate the symptoms and underlying causes of these debilitating conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.